Jan 8 (Reuters) - Catalyst Pharmaceuticals Inc :
* CATALYST PHARMACEUTICALS ANNOUNCES SETTLEMENT OF FIRDAPSE® (AMIFAMPRIDINE) PATENT LITIGATION WITH TEVA PHARMACEUTICALS
* CATALYST PHARMACEUTICALS: UNDER AGREEMENT, TEVA WILL NOT MARKET GENERIC VERSION OF FIRDAPSE IN U.S. EARLIER THAN FEB 25, 2035, IF APPROVED BY U.S. FDA
* CATALYST PHARMACEUTICALS INC - PENGING FIRDAPSE PATENT LITIGATION AGAINST HETERO AND LUPIN ONGOING
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.